{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T21:18:25Z","timestamp":1794691105426,"version":"4.9.1"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-77532-x","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:50:11Z","timestamp":1789055411000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Developing neoantigen cancer vaccines: where are we now?"],"prefix":"10.1038","volume":"17","author":[{"given":"Nune","family":"Markosyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7252-954X","authenticated-orcid":false,"given":"Robert H.","family":"Vonderheide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"77532_CR1","doi-asserted-by":"crossref","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).","DOI":"10.1126\/science.aar3593"},{"key":"77532_CR2","doi-asserted-by":"publisher","first-page":"e2311181","DOI":"10.1001\/jamanetworkopen.2023.11181","volume":"6","author":"C Aggarwal","year":"2023","unstructured":"Aggarwal, C. et al. Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy. JAMA Netw. Open 6, e2311181 (2023).","journal-title":"JAMA Netw. Open"},{"key":"77532_CR3","doi-asserted-by":"crossref","unstructured":"Gandara, D. R. et al. Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types. J. Immunother. Cancer 13, e010311 (2025).","DOI":"10.1136\/jitc-2024-010311"},{"key":"77532_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-24437-6","volume":"12","author":"A Kazama","year":"2022","unstructured":"Kazama, A. et al. Tumor-infiltrating immune cell status predicts successful response to immune checkpoint inhibitors in renal cell carcinoma. Sci. Rep. 12, 20386 (2022).","journal-title":"Sci. Rep."},{"key":"77532_CR5","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nm1100","volume":"10","author":"SA Rosenberg","year":"2004","unstructured":"Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909\u2013915 (2004).","journal-title":"Nat. Med."},{"key":"77532_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1158\/1940-6207.CAPR-12-0275","volume":"6","author":"T Kimura","year":"2013","unstructured":"Kimura, T. et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev. Res. 6, 18\u201326 (2013).","journal-title":"Cancer Prev. Res."},{"key":"77532_CR7","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1158\/1078-0432.CCR-22-3168","volume":"29","author":"RE Schoen","year":"2023","unstructured":"Schoen, R. E. et al. Randomized, double-blind, placebo-controlled trial of MUC1 peptide vaccine for prevention of recurrent colorectal adenoma. Clin. Cancer Res. 29, 1678\u20131688 (2023).","journal-title":"Clin. Cancer Res."},{"key":"77532_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.medj.2023.06.004","volume":"4","author":"RH Vonderheide","year":"2023","unstructured":"Vonderheide, R. H. Cancer vaccines are back, revitalized. Med. 4, 395\u2013397 (2023).","journal-title":"Med."},{"key":"77532_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl. J. Med. 363, 411\u2013422 (2010).","journal-title":"New Engl. J. Med."},{"key":"77532_CR10","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","volume":"28","author":"PW Kantoff","year":"2010","unstructured":"Kantoff, P. W. et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28, 1099\u20131105 (2010).","journal-title":"J. Clin. Oncol."},{"key":"77532_CR11","doi-asserted-by":"crossref","unstructured":"Shiller J. T. et al. Cancer vaccines. Cancer Cell 40. 559\u2013564 (2022).","DOI":"10.1016\/j.ccell.2022.05.015"},{"key":"77532_CR12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360\u2013378 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"77532_CR13","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1080\/14760584.2016.1176533","volume":"15","author":"P Vici","year":"2016","unstructured":"Vici, P. et al. Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. Expert Rev. Vaccines 15, 1327\u20131336 (2016).","journal-title":"Expert Rev. Vaccines"},{"key":"77532_CR14","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/cgt.2015.40","volume":"22","author":"AE Rice","year":"2015","unstructured":"Rice, A. E. et al. An HPV-E6\/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression. Cancer Gene Ther. 22, 454\u2013462 (2015).","journal-title":"Cancer Gene Ther."},{"key":"77532_CR15","doi-asserted-by":"publisher","first-page":"E5290","DOI":"10.1073\/pnas.1514418112","volume":"112","author":"T Bartkowiak","year":"2015","unstructured":"Bartkowiak, T. et al. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6\/E7 peptide vaccine. Proc. Natl. Acad. Sci. USA 112, E5290\u2013E5299 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77532_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1756-9966-33-29","volume":"33","author":"P Vici","year":"2014","unstructured":"Vici, P. et al. Immunologic treatments for precancerous lesions and uterine cervical cancer. J. Exp. Clin. Cancer Res. 33, 29 (2014).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"77532_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nrg.2016.49","volume":"17","author":"S Goodwin","year":"2016","unstructured":"Goodwin, S., McPherson, J. D. & McCombie, W. R. Coming of age: ten years of next-generation sequencing technologies. Nat. Rev. Genet. 17, 333\u2013351 (2016).","journal-title":"Nat. Rev. Genet."},{"key":"77532_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie, N. et al. Neoantigens: promising targets for cancer therapy. Signal Transduct. Target. Ther. 8, 9 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"77532_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0666-2","volume":"11","author":"MM Richters","year":"2019","unstructured":"Richters, M. M. et al. Best practices for bioinformatic characterization of neoantigens for clinical utility. Genome Med. 11, 56 (2019).","journal-title":"Genome Med."},{"key":"77532_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cels.2019.08.009","volume":"9","author":"LP Richman","year":"2019","unstructured":"Richman, L. P., Vonderheide, R. H. & Rech, A. J. Neoantigen dissimilarity to the self-proteome predicts immunogenicity and response to immune checkpoint blockade. Cell Syst. 9, 375\u2013382 (2019).","journal-title":"Cell Syst."},{"key":"77532_CR21","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214\u2013218 (2013).","journal-title":"Nature"},{"key":"77532_CR22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"77532_CR23","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nature14426","volume":"520","author":"S Kreiter","year":"2015","unstructured":"Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692\u2013696 (2015).","journal-title":"Nature"},{"key":"77532_CR24","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nm.3161","volume":"19","author":"PF Robbins","year":"2013","unstructured":"Robbins, P. F. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747\u2013752 (2013).","journal-title":"Nat. Med."},{"key":"77532_CR25","doi-asserted-by":"publisher","first-page":"e439","DOI":"10.1200\/JCO.2012.47.7521","volume":"31","author":"N van Rooij","year":"2013","unstructured":"van Rooij, N. et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439\u2013e442 (2013).","journal-title":"J. Clin. Oncol."},{"key":"77532_CR26","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran, E. et al. T-cell transfer therapy targeting mutant KRAS in cancer. New Engl. J. Med. 375, 2255\u20132262 (2016).","journal-title":"New Engl. J. Med."},{"key":"77532_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1158\/1078-0432.CCR-13-1736","volume":"20","author":"S Turcotte","year":"2014","unstructured":"Turcotte, S. et al. Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. Clin. Cancer Res. 20, 331\u2013343 (2014).","journal-title":"Clin. Cancer Res."},{"key":"77532_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nm.3773","volume":"21","author":"C Linnemann","year":"2015","unstructured":"Linnemann, C. et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat. Med. 21, 81\u201385 (2015).","journal-title":"Nat. Med."},{"key":"77532_CR29","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4049\/jimmunol.167.1.98","volume":"167","author":"V Deffrennes","year":"2001","unstructured":"Deffrennes, V. et al. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter. J. Immunol. 167, 98\u2013106 (2001).","journal-title":"J. Immunol."},{"key":"77532_CR30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222\u2013226 (2017).","journal-title":"Nature"},{"key":"77532_CR31","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1158\/2159-8290.CD-24-0158","volume":"14","author":"JF Gainor","year":"2024","unstructured":"Gainor, J. F. et al. T-cell responses to individualized neoantigen therapy mRNA-4157 (V940) alone or in combination with pembrolizumab in the phase 1 KEYNOTE-603 study. Cancer Discov. 14, 2209\u20132223 (2024).","journal-title":"Cancer Discov."},{"key":"77532_CR32","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632\u2013644 (2024).","journal-title":"Lancet"},{"key":"77532_CR33","unstructured":"Merck\/Moderna. Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III\/IV Melanoma Following Complete Resection (NCT3897881). https:\/\/www.merck.com\/news\/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient\/ (2026)."},{"key":"77532_CR34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"77532_CR35","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","volume":"27","author":"Z Hu","year":"2021","unstructured":"Hu, Z. et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat. Med. 27, 515\u2013525 (2021).","journal-title":"Nat. Med."},{"key":"77532_CR36","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183, 347\u2013362 (2020).","journal-title":"Cell"},{"key":"77532_CR37","doi-asserted-by":"crossref","unstructured":"Blass, E. et al. A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma. Cell 188, 5125\u20135141 (2025).","DOI":"10.1016\/j.cell.2025.06.019"},{"key":"77532_CR38","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.2023255","volume":"11","author":"SK Mork","year":"2022","unstructured":"Mork, S. K. et al. Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF(R)09b, in patients with metastatic melanoma. Oncoimmunology 11, 2023255 (2022).","journal-title":"Oncoimmunology"},{"key":"77532_CR39","doi-asserted-by":"crossref","unstructured":"Mork, S. K. et al. Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma. J. Immunother. Cancer 12, e008817 (2024).","DOI":"10.1136\/jitc-2024-008817"},{"key":"77532_CR40","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1126\/science.aaa3828","volume":"348","author":"BM Carreno","year":"2015","unstructured":"Carreno, B. M. et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803\u2013808 (2015).","journal-title":"Science"},{"key":"77532_CR41","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1126\/science.1251102","volume":"344","author":"E Tran","year":"2014","unstructured":"Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641\u2013645 (2014).","journal-title":"Science"},{"key":"77532_CR42","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.bcp.2019.07.015","volume":"168","author":"HP Gerber","year":"2019","unstructured":"Gerber, H. P., Sibener, L. V., Lee, L. J. & Gee, M. Intracellular targets as source for cleaner targets for the treatment of solid tumors. Biochem. Pharmacol. 168, 275\u2013284 (2019).","journal-title":"Biochem. Pharmacol."},{"key":"77532_CR43","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","volume":"55","author":"Y Lee","year":"2023","unstructured":"Lee, Y., Jeong, M., Park, J., Jung, H. & Lee, H. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp. Mol. Med. 55, 2085\u20132096 (2023).","journal-title":"Exp. Mol. Med."},{"key":"77532_CR44","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","volume":"639","author":"DA Braun","year":"2025","unstructured":"Braun, D. A. et al. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature 639, 474\u2013482 (2025).","journal-title":"Nature"},{"key":"77532_CR45","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00092","volume":"7","author":"JCF Quintanilha","year":"2023","unstructured":"Quintanilha, J. C. F. et al. Tumor mutational burden in real-world patients with pancreatic cancer: genomic alterations and predictive value for immune checkpoint inhibitor effectiveness. JCO Precis. Oncol. 7, e2300092 (2023).","journal-title":"JCO Precis. Oncol."},{"key":"77532_CR46","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.trecan.2018.04.001","volume":"4","author":"AH Morrison","year":"2018","unstructured":"Morrison, A. H., Byrne, K. T. & Vonderheide, R. H. Immunotherapy and prevention of pancreatic cancer. Trends Cancer 4, 418\u2013428 (2018).","journal-title":"Trends Cancer"},{"key":"77532_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2025.101049","volume":"5","author":"BP Conn","year":"2025","unstructured":"Conn, B. P. et al. Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discovery. Cell Rep. Methods 5, 101049 (2025).","journal-title":"Cell Rep. Methods"},{"key":"77532_CR48","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","volume":"31","author":"ZA Wainberg","year":"2025","unstructured":"Wainberg, Z. A. et al. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nat. Med. 31, 3648\u20133653 (2025).","journal-title":"Nat. Med."},{"key":"77532_CR49","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nature24462","volume":"551","author":"VP Balachandran","year":"2017","unstructured":"Balachandran, V. P. et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551, 512\u2013516 (2017).","journal-title":"Nature"},{"key":"77532_CR50","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"77532_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2013.8","volume":"2","author":"J Bhadury","year":"2013","unstructured":"Bhadury, J., Lopez, M. D., Muralidharan, S. V., Nilsson, L. M. & Nilsson, J. A. Identification of tumorigenic and therapeutically actionable mutations in transplantable mouse tumor cells by exome sequencing. Oncogenesis 2, e44 (2013).","journal-title":"Oncogenesis"},{"key":"77532_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02424-0","volume":"9","author":"M Efremova","year":"2018","unstructured":"Efremova, M. et al. Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution. Nat. Commun. 9, 32 (2018).","journal-title":"Nat. Commun."},{"key":"77532_CR53","doi-asserted-by":"crossref","unstructured":"Kinkead, H. L. et al. Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. JCI Insight 3, e122857 (2018).","DOI":"10.1172\/jci.insight.122857"},{"key":"77532_CR54","doi-asserted-by":"crossref","unstructured":"Huff, A. L. et al. CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacy. JCI Insight 8, e174027 (2023).","DOI":"10.1172\/jci.insight.174027"},{"key":"77532_CR55","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna, Z. et al. RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer. Nature 639, 1042\u20131051 (2025).","journal-title":"Nature"},{"key":"77532_CR56","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park, W., Chawla, A. & O\u2019Reilly, E. M. Pancreatic cancer: a review. JAMA 326, 851\u2013862 (2021).","journal-title":"JAMA"},{"key":"77532_CR57","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan, H. et al. IDH1 and IDH2 mutations in gliomas. New Engl. J. Med. 360, 765\u2013773 (2009).","journal-title":"New Engl. J. Med."},{"key":"77532_CR58","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-021-03363-z","volume":"592","author":"M Platten","year":"2021","unstructured":"Platten, M. et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature 592, 463\u2013468 (2021).","journal-title":"Nature"},{"key":"77532_CR59","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","volume":"565","author":"N Hilf","year":"2019","unstructured":"Hilf, N. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240\u2013245 (2019).","journal-title":"Nature"},{"key":"77532_CR60","doi-asserted-by":"crossref","unstructured":"Sipos, D. et al. Glioblastoma: clinical presentation, multidisciplinary management, and long-term outcomes. Cancers 17, 146 (2025).","DOI":"10.3390\/cancers17010146"},{"key":"77532_CR61","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","volume":"40","author":"MM Awad","year":"2022","unstructured":"Awad, M. M. et al. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell 40, 1010\u20131026 (2022).","journal-title":"Cancer Cell"},{"key":"77532_CR62","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234\u2013239 (2019).","journal-title":"Nature"},{"key":"77532_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51315-8","volume":"15","author":"P Latzer","year":"2024","unstructured":"Latzer, P. et al. A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine. Nat. Commun. 15, 6870 (2024).","journal-title":"Nat. Commun."},{"key":"77532_CR64","doi-asserted-by":"crossref","unstructured":"Garfinkle, E. et al. Perales-Linares, R., Gimple, R., Yan, J. & Navarro, J. CTIM-33. Personalized multivalent DNA vaccination safely induces broad neoantigen-specific T cell responses in newly diagnosed MGMT unmethylated glioblastoma in a clinically relevant time scale. In Proc. SNO Annual Meeting Vol. 27 (Oxford University Press, 2025).","DOI":"10.1093\/neuonc\/noaf201.0490"},{"key":"77532_CR65","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/labinvest.3700233","volume":"85","author":"D Zagzag","year":"2005","unstructured":"Zagzag, D. et al. Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab. Investig. 85, 328\u2013341 (2005).","journal-title":"Lab. Investig."},{"key":"77532_CR66","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ccell.2022.12.007","volume":"41","author":"M Kilian","year":"2023","unstructured":"Kilian, M. et al. MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors. Cancer Cell 41, 235\u2013251 (2023).","journal-title":"Cancer Cell"},{"key":"77532_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-024-01388-3","volume":"16","author":"X Zhang","year":"2024","unstructured":"Zhang, X. et al. Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients. Genome Med. 16, 131 (2024).","journal-title":"Genome Med."},{"key":"77532_CR68","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent, R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429\u20134434 (2007).","journal-title":"Clin. Cancer Res."},{"key":"77532_CR69","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s12672-025-04251-y","volume":"17","author":"H Gao","year":"2026","unstructured":"Gao, H., Yang, J. & Li, Y. Triple-negative breast cancer survival outcomes: prognostic model validated with SEER database. Discov. Oncol. 17, 258 (2026).","journal-title":"Discov. Oncol."},{"key":"77532_CR70","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","volume":"30","author":"M Yarchoan","year":"2024","unstructured":"Yarchoan, M. et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial. Nat. Med. 30, 1044\u20131053 (2024).","journal-title":"Nat. Med."},{"key":"77532_CR71","doi-asserted-by":"publisher","first-page":"175883592093761","DOI":"10.1177\/1758835920937612","volume":"12","author":"B Zhao","year":"2020","unstructured":"Zhao, B., Zhao, H. & Zhao, J. Efficacy of PD-1\/PD-L1 blockade monotherapy in clinical trials. Ther. Adv. Med. Oncol. 12, 1758835920937612 (2020).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"77532_CR72","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1158\/2159-8290.CD-24-0934","volume":"15","author":"M Saxena","year":"2025","unstructured":"Saxena, M. et al. PGV001, a multi-peptide personalized neoantigen vaccine platform: phase I study in patients with solid and hematologic malignancies in the adjuvant setting. Cancer Discov. 15, 930\u2013947 (2025).","journal-title":"Cancer Discov."},{"key":"77532_CR73","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41392-025-02204-z","volume":"10","author":"E Schaeffeler","year":"2025","unstructured":"Schaeffeler, E., Walz, J. & Schwab, M. Personalized cancer vaccination is emerging: lessons learnt from renal cancer and challenges for broader application. Signal Transduct. Target. Ther. 10, 107 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"77532_CR74","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk3487","volume":"388","author":"ZA Ely","year":"2025","unstructured":"Ely, Z. A. et al. Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition. Science 388, eadk3487 (2025).","journal-title":"Science"},{"key":"77532_CR75","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1146\/annurev-med-071723-045853","volume":"77","author":"H Sultan","year":"2026","unstructured":"Sultan, H. & Schreiber, R. D. Cancer neoantigen vaccines emerge efficacious. Annu. Rev. Med. 77, 297\u2013314 (2026).","journal-title":"Annu. Rev. Med."},{"key":"77532_CR76","doi-asserted-by":"crossref","unstructured":"Esprit, A. et al. Neo-antigen mRNA vaccines. Vaccines 8, 776 (2020).","DOI":"10.3390\/vaccines8040776"},{"key":"77532_CR77","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","volume":"24","author":"PD Katsikis","year":"2024","unstructured":"Katsikis, P. D., Ishii, K. J. & Schliehe, C. Challenges in developing personalized neoantigen cancer vaccines. Nat. Rev. Immunol. 24, 213\u2013227 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"77532_CR78","doi-asserted-by":"crossref","unstructured":"Gfeller, D., Racle, J., Harari, A. & Croce, G. Advances in predicting T cell epitope recognition for cancer immunotherapy. Nat. Cancer 7, 711\u2013722 (2026).","DOI":"10.1038\/s43018-026-01144-z"},{"key":"77532_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1617654","volume":"16","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. Advances and challenges in neoantigen prediction for cancer immunotherapy. Front. Immunol. 16, 1617654 (2025).","journal-title":"Front. Immunol."},{"key":"77532_CR80","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/onco.13680","volume":"26","author":"T Janowitz","year":"2021","unstructured":"Janowitz, T., Kleeman, S. & Vonderheide, R. H. Reconsidering dexamethasone for antiemesis when combining chemotherapy and immunotherapy. Oncologist 26, 269\u2013273 (2021).","journal-title":"Oncologist"},{"key":"77532_CR81","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1158\/2767-9764.CRC-25-0051","volume":"5","author":"L Polyakov","year":"2025","unstructured":"Polyakov, L. et al. Impact of glucocorticoids on immune checkpoint inhibitor efficacy and circulating biomarkers in non-small cell lung cancer patients. Cancer Res. Commun. 5, 1082\u20131094 (2025).","journal-title":"Cancer Res. Commun."},{"key":"77532_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19933-0","volume":"11","author":"YH Park","year":"2020","unstructured":"Park, Y. H. et al. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. Nat. Commun. 11, 6175 (2020).","journal-title":"Nat. Commun."},{"key":"77532_CR83","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1172\/JCI134915","volume":"130","author":"G Cafri","year":"2020","unstructured":"Cafri, G. et al. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J. Clin. Investig. 130, 5976\u20135988 (2020).","journal-title":"J. Clin. Investig."},{"key":"77532_CR84","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41590-019-0441-y","volume":"20","author":"V Verma","year":"2019","unstructured":"Verma, V. et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1(+)CD38(hi) cells and anti-PD-1 resistance. Nat. Immunol. 20, 1231\u20131243 (2019).","journal-title":"Nat. Immunol."},{"key":"77532_CR85","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41586-025-10004-2","volume":"651","author":"U Sahin","year":"2026","unstructured":"Sahin, U. et al. Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC. Nature 651, 1088\u20131096 (2026).","journal-title":"Nature"},{"key":"77532_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00433-9","volume":"7","author":"E Salvatori","year":"2022","unstructured":"Salvatori, E. et al. Neoantigen cancer vaccine augments anti-CTLA-4 efficacy. NPJ Vaccines 7, 15 (2022).","journal-title":"NPJ Vaccines"},{"key":"77532_CR87","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","volume":"28","author":"CD Palmer","year":"2022","unstructured":"Palmer, C. D. et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 28, 1619\u20131629 (2022).","journal-title":"Nat. Med."},{"key":"77532_CR88","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1158\/2767-9764.CRC-25-0327","volume":"5","author":"P Gowda","year":"2025","unstructured":"Gowda, P., Govindu, S. R. & Hsiehchen, D. Impact of tumor burden on immune checkpoint and conventional therapy responses and outcomes. Cancer Res. Commun. 5, 1978\u20131983 (2025).","journal-title":"Cancer Res. Commun."},{"key":"77532_CR89","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejca.2020.08.026","volume":"139","author":"P Tarantino","year":"2020","unstructured":"Tarantino, P. et al. Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents. Eur. J. Cancer 139, 92\u201398 (2020).","journal-title":"Eur. J. Cancer"},{"key":"77532_CR90","doi-asserted-by":"crossref","unstructured":"Secli, L. et al. Neoadjuvant personalized viral vaccine prevents tumor relapse in checkpoint-resistant murine melanoma model. J. Immunother. Cancer 13, e013035 (2025).","DOI":"10.1136\/jitc-2025-013035"},{"key":"77532_CR91","doi-asserted-by":"crossref","unstructured":"Jo, S. et al. mRNA vaccines engage unconventional pathways in CD8(+) T cell priming. Nature 654, 485\u2013494 (2026).","DOI":"10.1038\/s41586-026-10353-6"},{"key":"77532_CR92","doi-asserted-by":"publisher","unstructured":"Marks, A. et al. mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression. Nat. Biotechnol. 1\u201315 https:\/\/doi.org\/10.1038\/s41587-026-03099-z (2026).","DOI":"10.1038\/s41587-026-03099-z"},{"key":"77532_CR93","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41585-023-00739-w","volume":"20","author":"I Rastogi","year":"2023","unstructured":"Rastogi, I., Muralidhar, A. & McNeel, D. G. Vaccines as treatments for prostate cancer. Nat. Rev. Urol. 20, 544\u2013559 (2023).","journal-title":"Nat. Rev. Urol."},{"key":"77532_CR94","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1600-065X.1995.tb00077.x","volume":"145","author":"OJ Finn","year":"1995","unstructured":"Finn, O. J. et al. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol. Rev. 145, 61\u201389 (1995).","journal-title":"Immunol. Rev."},{"key":"77532_CR95","doi-asserted-by":"publisher","first-page":"20422","DOI":"10.1073\/pnas.0810777105","volume":"105","author":"O Hofmann","year":"2008","unstructured":"Hofmann, O. et al. Genome-wide analysis of cancer\/testis gene expression. Proc. Natl. Acad. Sci. USA 105, 20422\u201320427 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77532_CR96","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","volume":"8","author":"T Fan","year":"2023","unstructured":"Fan, T. et al. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct. Target. Ther. 8, 450 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"77532_CR97","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1084\/jem.179.3.1005","volume":"179","author":"AB Bakker","year":"1994","unstructured":"Bakker, A. B. et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179, 1005\u20131009 (1994).","journal-title":"J. Exp. Med."},{"key":"77532_CR98","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/14728222.2023.2218613","volume":"27","author":"S Halder","year":"2023","unstructured":"Halder, S. et al. Targeting the EGFR signaling pathway in cancer therapy: what\u2019s new in 2023? Expert Opin. Ther. Targets 27, 305\u2013324 (2023).","journal-title":"Expert Opin. Ther. Targets"},{"key":"77532_CR99","doi-asserted-by":"crossref","unstructured":"Uribe, M. L., Marrocco, I. & Yarden, Y. EGFR in cancer: signaling mechanisms, drugs, and acquired resistance. Cancers 13, 2748 (2021).","DOI":"10.3390\/cancers13112748"},{"key":"77532_CR100","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1007\/s00018-021-03783-0","volume":"78","author":"SC Akincilar","year":"2021","unstructured":"Akincilar, S. C., Chan, C. H. T., Ng, Q. F., Fidan, K. & Tergaonkar, V. Non-canonical roles of canonical telomere binding proteins in cancers. Cell Mol. Life Sci. 78, 4235\u20134257 (2021).","journal-title":"Cell Mol. Life Sci."},{"key":"77532_CR101","first-page":"103","volume":"7","author":"RH Vonderheide","year":"2007","unstructured":"Vonderheide, R. H. Universal tumor antigens for cancer vaccination: targeting telomerase for immunoprevention. Discov. Med. 7, 103\u2013108 (2007).","journal-title":"Discov. Med."},{"key":"77532_CR102","doi-asserted-by":"publisher","first-page":"djv086","DOI":"10.1093\/jnci\/djv086","volume":"107","author":"M Saraiya","year":"2015","unstructured":"Saraiya, M. et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J. Natl. Cancer Inst. 107, djv086 (2015).","journal-title":"J. Natl. Cancer Inst."},{"key":"77532_CR103","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1016\/j.cell.2022.06.035","volume":"185","author":"MC Sellars","year":"2022","unstructured":"Sellars, M. C., Wu, C. J. & Fritsch, E. F. Cancer vaccines: building a bridge over troubled waters. Cell 185, 2770\u20132788 (2022).","journal-title":"Cell"},{"key":"77532_CR104","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1084\/jem.20141308","volume":"211","author":"F Duan","year":"2014","unstructured":"Duan, F. et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J. Exp. Med. 211, 2231\u20132248 (2014).","journal-title":"J. Exp. Med."},{"key":"77532_CR105","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/2326-6066.CIR-17-0559","volume":"6","author":"AJ Rech","year":"2018","unstructured":"Rech, A. J. et al. Tumor immunity and survival as a function of alternative neopeptides in human cancer. Cancer Immunol. Res. 6, 276\u2013287 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"77532_CR106","doi-asserted-by":"publisher","first-page":"836821","DOI":"10.3389\/fonc.2022.836821","volume":"12","author":"ES Borden","year":"2022","unstructured":"Borden, E. S., Buetow, K. H., Wilson, M. A. & Hastings, K. T. Cancer neoantigens: challenges and future directions for prediction, prioritization, and validation. Front. Oncol. 12, 836821 (2022).","journal-title":"Front. Oncol."},{"key":"77532_CR107","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nri.2017.131","volume":"18","author":"Z Hu","year":"2018","unstructured":"Hu, Z., Ott, P. A. & Wu, C. J. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat. Rev. Immunol. 18, 168\u2013182 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"77532_CR108","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","volume":"9","author":"LM Liau","year":"2023","unstructured":"Liau, L. M. et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol. 9, 112\u2013121 (2023).","journal-title":"JAMA Oncol."},{"key":"77532_CR109","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41591-024-02851-9","volume":"30","author":"AR Rappaport","year":"2024","unstructured":"Rappaport, A. R. et al. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 30, 1013\u20131022 (2024).","journal-title":"Nat. Med."},{"key":"77532_CR110","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines\u2014a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"77532_CR111","doi-asserted-by":"publisher","first-page":"115175","DOI":"10.1016\/j.addr.2023.115175","volume":"205","author":"P Sharma","year":"2024","unstructured":"Sharma, P., Hoorn, D., Aitha, A., Breier, D. & Peer, D. The immunostimulatory nature of mRNA lipid nanoparticles. Adv. Drug Deliv. Rev. 205, 115175 (2024).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"77532_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114288","volume":"388","author":"F Han","year":"2025","unstructured":"Han, F. et al. Microorganism delivery of cancer vaccines. J. Control Release 388, 114288 (2025).","journal-title":"J. Control Release"},{"key":"77532_CR113","doi-asserted-by":"crossref","unstructured":"Jung, D. et al. CD40 agonistic-monovalent streptavidin fusion antibody for targeted neoantigen peptide delivery and potent cancer vaccination. J. Control Release 396, 115053 (2026).","DOI":"10.1016\/j.jconrel.2026.115053"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77532-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77532-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77532-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:02:21Z","timestamp":1789059741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77532-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":113,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77532"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77532-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Vonderheide has received consulting fees from Astellas, EMD Serono, Grey Wolf Therapeutics and Crossbow Therapeutics, research funding from Revolution Medicines, is an inventor on patents relating to cancer cellular immunotherapy, cancer vaccines, cancer interception and KRAS immune epitopes and receives royalties from Children\u2019s Hospital Boston for a licensed research-only monoclonal antibody.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9700"}}